MOR00208: Phase II/III started

MorphoSys began the open-label, international Phase II/III B-MIND trial to compare 12 mg/kg IV MOR208 plus Treanda bendamustine vs. IV Rituxan/ MabThera rituximab plus Treanda in about 330 patients ...